JP2007529478A5 - - Google Patents

Download PDF

Info

Publication number
JP2007529478A5
JP2007529478A5 JP2007503361A JP2007503361A JP2007529478A5 JP 2007529478 A5 JP2007529478 A5 JP 2007529478A5 JP 2007503361 A JP2007503361 A JP 2007503361A JP 2007503361 A JP2007503361 A JP 2007503361A JP 2007529478 A5 JP2007529478 A5 JP 2007529478A5
Authority
JP
Japan
Prior art keywords
use according
product
sorbitan
per dose
sorbitan derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007503361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529478A (ja
Filing date
Publication date
Priority claimed from FI20045076A external-priority patent/FI20045076L/fi
Application filed filed Critical
Publication of JP2007529478A publication Critical patent/JP2007529478A/ja
Publication of JP2007529478A5 publication Critical patent/JP2007529478A5/ja
Pending legal-status Critical Current

Links

JP2007503361A 2004-03-15 2005-03-14 肥満を治療するための組成物、組成物の使用及び方法 Pending JP2007529478A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20045076A FI20045076L (fi) 2004-03-15 2004-03-15 Funktionaalinen elintarvike
PCT/FI2005/000151 WO2005087025A1 (en) 2004-03-15 2005-03-14 Composition; use of a composition and a method for treating obesity

Publications (2)

Publication Number Publication Date
JP2007529478A JP2007529478A (ja) 2007-10-25
JP2007529478A5 true JP2007529478A5 (https=) 2008-05-01

Family

ID=32039504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503361A Pending JP2007529478A (ja) 2004-03-15 2005-03-14 肥満を治療するための組成物、組成物の使用及び方法

Country Status (14)

Country Link
US (1) US20080038318A1 (https=)
EP (1) EP1729598B1 (https=)
JP (1) JP2007529478A (https=)
CN (1) CN1953670B (https=)
AT (1) ATE407575T1 (https=)
AU (1) AU2005220626B2 (https=)
BR (1) BRPI0509243A (https=)
CA (1) CA2559175A1 (https=)
DE (1) DE602005009676D1 (https=)
DK (1) DK1729598T3 (https=)
ES (1) ES2314636T3 (https=)
FI (1) FI20045076L (https=)
RU (1) RU2386365C2 (https=)
WO (1) WO2005087025A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010004792A (ja) * 2008-06-26 2010-01-14 Taiyo Kagaku Co Ltd 液状食品組成物のチューブ流動性改善剤
US8329455B2 (en) 2011-07-08 2012-12-11 Aikan North America, Inc. Systems and methods for digestion of solid waste
EP2934495B1 (en) 2012-12-21 2017-07-19 National Health Research Institutes Mesoporous silica nanoparticles for oil absorption

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273795A (en) * 1979-11-19 1981-06-16 Standard Brands Incorporated Low-fat spread and process
US4803087A (en) * 1987-07-21 1989-02-07 Ppg Industries, Inc. Composition and method for producing vitamin-enriched milk
JPH03187340A (ja) * 1989-12-15 1991-08-15 Tsukishima Shokuhin Kogyo Kk 超泡性乳化油脂及びスポンジケーキ類の製造法
JPH06227996A (ja) * 1993-01-28 1994-08-16 Nippon Yakuhin Kogyo Kk 体重抑制剤
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US6214349B1 (en) * 1996-03-12 2001-04-10 Nature's Sunshine Products, Inc. Composition for limiting the assimilation of dietary fat and methods of making and using same
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition

Similar Documents

Publication Publication Date Title
NO20075834L (no) Doseringsformer for risendronat
UA98121C2 (ru) Термообработанный продукт из злаков, содержащий начинку
JP2010522242A5 (https=)
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
FI4349369T3 (fi) Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
JP2014198723A5 (https=)
JP2011510922A5 (https=)
JP2007517039A5 (https=)
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
JP2019156793A5 (https=)
IL210386A (en) Indole history, their medicinal preparations, and their use in the preparation of drugs for the treatment or prevention of neurodegenerative diseases
JP2005524629A5 (https=)
JP2007529478A5 (https=)
HRP20131070T1 (hr) Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
JP2013528627A5 (https=)
PL2193789T3 (pl) Zastosowanie 5-metylo-1,3-benzenodiolu lub jego pochodnych w przygotowaniu leku i funkcjonalnej żywności do leczenia lub zapobiegania depresji
JP2013032308A5 (https=)
DE60212015D1 (de) Autonomsystem kontrollagentien und gesundheitsgetränke und -nahrungsmittel
JP2005232125A5 (https=)
JP2006335648A5 (https=)
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
EP1609780A4 (en) MEANS FOR THE TREATMENT OF DIABETES
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
JP2006508994A5 (https=)